The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro

Biochemical and Biophysical Research Communications

Volumn 440, Issue 4, 2013, Pages 701-706

  Li, Qiang ^a   Song, Xin Mao ^a   Ji, Yang Yang ^a   Jiang, Hui ^a   Xu, Lin Gen ^a  

^a JINSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

AZD8055; Cancer cell death; Head and neck squamous cell carcinoma; JNK; mTOR

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; AZD 2014; AZD 8055; EVEROLIMUS; INK 128; RAPAMYCIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CELL CULTURE; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA CELL GROWTH; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR GROWTH;

MAMMALIA; MUS;

EID: 84887110385     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.09.130     Document Type: Article

References (34)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics CA Cancer J. Clin. 63 2013 2013 11 30
2. L. Mao, W.K. Hong, and V.A. Papadimitrakopoulou Focus on head and neck cancer Cancer Cell 5 2004 311 316
3. P.M. Stell Survival times in end-stage head and neck cancer Eur. J. Surg. Oncol. 15 1989 407 410
4. S. Aggarwal, Y. Takada, S. Singh, J.N. Myers, and B.B. Aggarwal Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling Int. J. Cancer 111 2004 679 692
5. P.M. Stell Time to recurrence of squamous cell carcinoma of the head and neck Head Neck 13 1991 277 281
6. A. Bozec, F. Peyrade, J.L. Fischel, and G. Milano Emerging molecular targeted therapies in the treatment of head and neck cancer Expert Opin. Emerg. Drugs 14 2009 299 310
7. M. Goerner, T.Y. Seiwert, and H. Sudhoff Molecular targeted therapies in head and neck cancer - an update of recent developments Head Neck Oncol. 2 2010 8
8. D. Sano, D.R. Fooshee, M. Zhao, G.A. Andrews, M.J. Frederick, C. Galer, Z.L. Milas, P.K. Morrow, and J.N. Myers Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model Head Neck 33 2011 349 358
9. A.A. Molinolo, S.M. Hewitt, P. Amornphimoltham, S. Keelawat, S. Rangdaeng, A. Meneses Garcia, A.R. Raimondi, R. Jufe, M. Itoiz, Y. Gao, D. Saranath, G.S. Kaleebi, G.H. Yoo, L. Leak, E.M. Myers, S. Shintani, D. Wong, H.D. Massey, W.A. Yeudall, F. Lonardo, J. Ensley, and J.S. Gutkind Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative Clin. Cancer Res. 13 2007 4964 4973
10. P. Amornphimoltham, V. Patel, A. Sodhi, N.G. Nikitakis, J.J. Sauk, E.A. Sausville, A.A. Molinolo, and J.S. Gutkind Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck Cancer Res. 65 2005 9953 9961
11. C.G. Proud MTORC1 signalling and mRNA translation Biochem. Soc. Trans. 37 2009 227 231
12. P. Wu, and Y.Z. Hu PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress Curr. Med. Chem. 17 2010 4326 4341
13. T.A. Yap, M.D. Garrett, M.I. Walton, F. Raynaud, J.S. de Bono, and P. Workman Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises Curr. Opin. Pharmacol. 8 2008 393 412
14. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 2007 9 22
15. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
16. L. Willems, N. Chapuis, A. Puissant, T.T. Maciel, A.S. Green, N. Jacque, C. Vignon, S. Park, S. Guichard, O. Herault, A. Fricot, O. Hermine, I.C. Moura, P. Auberger, N. Ifrah, F. Dreyfus, D. Bonnet, C. Lacombe, P. Mayeux, D. Bouscary, and J. Tamburini The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia Leukemia 26 2012 1195 1202
17. P. Sini, D. James, C. Chresta, and S. Guichard Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells Autophagy 6 2010 553 554
18. C.M. Chresta, B.R. Davies, I. Hickson, T. Harding, S. Cosulich, S.E. Critchlow, J.P. Vincent, R. Ellston, D. Jones, P. Sini, D. James, Z. Howard, P. Dudley, G. Hughes, L. Smith, S. Maguire, M. Hummersone, K. Malagu, K. Menear, R. Jenkins, M. Jacobsen, G.C. Smith, S. Guichard, and M. Pass AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity Cancer Res. 70 2010 288 298
19. H. Xiong, Z.G. Zhang, X.Q. Tian, D.F. Sun, Q.C. Liang, Y.J. Zhang, R. Lu, Y.X. Chen, and J.Y. Fang Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells Neoplasia 10 2008 287 297
20. Y.L. Yang, C. Ji, Z.G. Bi, C.C. Lu, R. Wang, B. Gu, and L. Cheng Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells PLoS ONE 8 2013 e54736
21. K. Sommer, S.O. Peters, I.H. Robins, M. Raap, G.J. Wiedemann, S. Remmert, P. Sieg, C. Bittner, and T. Feyerabend A preclinical model for experimental chemotherapy of human head and neck cancer Int. J. Oncol. 18 2001 1145 1149
22. F. Bruzzese, E. Di Gennaro, A. Avallone, S. Pepe, C. Arra, M. Caraglia, P. Tagliaferri, and A. Budillon Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo Clin. Cancer Res. 12 2006 617 625
23. H.Y. Lee, S.H. Oh, J.K. Woo, W.Y. Kim, C.S. Van Pelt, R.E. Price, D. Cody, H. Tran, J.M. Pezzuto, R.M. Moriarty, and W.K. Hong Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis J. Natl Cancer Inst. 97 2005 1695 1699
24. A. Tripathi Bhar, S. Banerjee, N. Chunder, A. Roy, A. Sengupta, B. Roy, S. Roychowdhury, and C.K. Panda Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients J. Cancer Res. Clin. Oncol. 129 2003 642 650
25. C. Freudlsperger, J.R. Burnett, J.A. Friedman, V.R. Kannabiran, Z. Chen, and C. Van Waes EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy Expert Opin. Ther. Targets 15 2011 63 74
26. K.G. Pike, K. Malagu, M.G. Hummersone, K.A. Menear, H.M. Duggan, S. Gomez, N.M. Martin, L. Ruston, S.L. Pass, and M. Pass Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014 Bioorg. Med. Chem. Lett. 23 2013 1212 1216
27. C. Garcia-Garcia, Y.H. Ibrahim, V. Serra, M.T. Calvo, M. Guzman, J. Grueso, C. Aura, J. Perez, K. Jessen, Y. Liu, C. Rommel, J. Tabernero, J. Baselga, and M. Scaltriti Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy Clin. Cancer Res. 18 2012 2603 2612
28. M. Verheij, R. Bose, X.H. Lin, B. Yao, W.D. Jarvis, S. Grant, M.J. Birrer, E. Szabo, L.I. Zon, J.M. Kyriakis, A. Haimovitz-Friedman, Z. Fuks, and R.N. Kolesnick Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis Nature 380 1996 75 79
29. A. Jemal, T. Murray, A. Samuels, A. Ghafoor, E. Ward, and M.J. Thun Cancer statistics CA Cancer J. Clin. 53 2003 2003 5 26
30. M.A. Simmonds Cancer statistics, 2003: further decrease in mortality rate, increase in persons living with cancer CA Cancer J. Clin. 53 2003 4
31. B. Brockstein, D.J. Haraf, A.W. Rademaker, M.S. Kies, K.M. Stenson, F. Rosen, B.B. Mittal, H. Pelzer, B.B. Fung, M.E. Witt, B. Wenig, L. Portugal, R.W. Weichselbaum, and E.E. Vokes Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience Ann. Oncol. 15 2004 1179 1186
32. K.D. Hunter, E.K. Parkinson, and P.R. Harrison Profiling early head and neck cancer Nat. Rev. Cancer 5 2005 127 135
33. K.E. O'Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, D. Smith, H. Lane, F. Hofmann, D.J. Hicklin, D.L. Ludwig, J. Baselga, and N. Rosen MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res. 66 2006 1500 1508
34. A. Carracedo, L. Ma, J. Teruya-Feldstein, F. Rojo, L. Salmena, A. Alimonti, A. Egia, A.T. Sasaki, G. Thomas, S.C. Kozma, A. Papa, C. Nardella, L.C. Cantley, J. Baselga, and P.P. Pandolfi Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J. Clin. Invest. 118 2008 3065 3074